Bioline

BioLineRx Has Dosed the First GLIX1 Patient, but Value Still Waits for Data and Funding

First-patient dosing moves GLIX1 into active clinical execution, but it does not create revenue or solve Tetragon funding. The value picture will begin to change only if 2027 Phase 1 data support safety, dose selection and early response.